

Suanna Steeby Bruinooge

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7150656/publications.pdf>

Version: 2024-02-01

79
papers

3,951
citations

186265

28
h-index

123424

61
g-index

79
all docs

79
docs citations

79
times ranked

6547
citing authors

#	ARTICLE	IF	CITATIONS
1	Changes Over Time in COVID-19 Severity and Mortality in Patients Undergoing Cancer Treatment in the United States: Initial Report From the ASCO Registry. JCO Oncology Practice, 2022, 18, e426-e441.	2.9	16
2	Defining comprehensive biomarker-related testing and treatment practices for advanced non-small cell lung cancer: Results of a survey of U.S. oncologists. Cancer Medicine, 2022, 11, 530-538.	2.8	28
3	Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement. Journal of Clinical Oncology, 2022, 40, 2163-2171.	1.6	68
4	Associations between biomarker testing and characteristics of patients with metastatic non-small cell lung cancer (mNSCLC): An analysis of CancerLinQ Discovery (CLQD) data.. Journal of Clinical Oncology, 2022, 40, 9127-9127.	1.6	0
5	Assessing feasibility and utility of an implicit bias training program for addressing disparities in cancer clinical trial participation.. Journal of Clinical Oncology, 2022, 40, e18599-e18599.	1.6	1
6	Availability of data for screening, offering, and consenting patients to cancer clinical trials: Report from an ASCO-ACCC collaboration.. Journal of Clinical Oncology, 2022, 40, 6530-6530.	1.6	2
7	Presentation, management, and outcome of COVID-19 among patients with cancer in the Middle East and North Africa (MENA) region.. Journal of Clinical Oncology, 2022, 40, e18797-e18797.	1.6	0
8	COVID-19 vaccine uptake in patients with cancer and Sars-Cov-2 infection in 2020: Results from the ASCO registry.. Journal of Clinical Oncology, 2022, 40, e18713-e18713.	1.6	0
9	Oncologists' perspectives on individualizing dose selection for patients with metastatic cancer.. Journal of Clinical Oncology, 2022, 40, 1531-1531.	1.6	0
10	Breakthrough COVID-19 cases and hospitalization risk: ASCO COVID-19 registry.. Journal of Clinical Oncology, 2022, 40, e18807-e18807.	1.6	0
11	American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care. Journal of Clinical Oncology, 2021, 39, 155-169.	1.6	65
12	Recommendations to Streamline and Standardize Clinical Trial Site Feasibility Assessments: An ASCO Research Statement. JCO Oncology Practice, 2021, 17, 41-51.	2.9	3
13	Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group. Clinical Cancer Research, 2021, 27, 2424-2429.	7.0	35
14	Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO-Friends of Cancer Research Joint Research Statement. Clinical Cancer Research, 2021, 27, 2394-2399.	7.0	47
15	Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non-Small Cell Lung Cancer: Real-World Analysis of Select ASCO-Friends of Cancer Research Recommendations. Clinical Cancer Research, 2021, 27, 2430-2434.	7.0	28
16	Identification of Transgender People With Cancer in Electronic Health Records: Recommendations Based on CancerLinQ Observations. JCO Oncology Practice, 2021, 17, e336-e342.	2.9	7
17	ASCO's Selection of Oncologist Workforce Data Source. JCO Oncology Practice, 2021, 17, 295-296.	2.9	0
18	Physician concern about delaying lung cancer treatment while awaiting biomarker testing: Results of a survey of U.S. oncologists.. Journal of Clinical Oncology, 2021, 39, 9067-9067.	1.6	2

#	ARTICLE	IF	CITATIONS
19	Mortality risk for patients undergoing cancer treatment who acquire SARS-CoV-2: ASCO registry.. Journal of Clinical Oncology, 2021, 39, 6509-6509.	1.6	0
20	Challenges and opportunities to developing a frailty index using electronic health record data. Journal of Geriatric Oncology, 2021, 12, 851-854.	1.0	7
21	Accessing Targeted Therapies: A Potential Roadblock to Implementing Precision Oncology?. JCO Oncology Practice, 2021, 17, e999-e1011.	2.9	3
22	Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Journal of Clinical Oncology, 2021, 39, 2443-2451.	1.6	97
23	Discrepancies in Financial Self-Disclosures and Open Payments Reporting Among Authors of Clinical Oncology Research Studies. Journal of Clinical Oncology, 2020, 38, 480-487.	1.6	3
24	Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Targeted Oncology, 2020, 15, 743-750.	3.6	25
25	Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and Long-Term Opportunities for Transformation: Findings From an American Society of Clinical Oncology Survey. JCO Oncology Practice, 2020, 16, 417-421.	2.9	158
26	Palbociclib in Patients With Non-“Small-Cell Lung Cancer With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology, 2020, 4, 757-766.	3.0	52
27	Annual trends in opioid prescribing for patients (Pts) with metastatic non-small cell lung cancer (mNSCLC): Cancerlinq data analysis, 2010 to 2017.. Journal of Clinical Oncology, 2020, 38, 2076-2076.	1.6	0
28	Trends in immunotherapy use in patients with advanced non-small cell lung cancer (aNSCLC) patients: Analysis of real-world data.. Journal of Clinical Oncology, 2020, 38, e19311-e19311.	1.6	1
29	NGS testing use and results: A survey of U.S. oncologists.. Journal of Clinical Oncology, 2020, 38, e19145-e19145.	1.6	1
30	Identification of transgender people with cancer in electronic health records (EHR): Recommendations based on CancerLinQ observations.. Journal of Clinical Oncology, 2020, 38, e19046-e19046.	1.6	0
31	Determining If a Somatic Tumor Mutation Is Targetable and Options for Accessing Targeted Therapies. Journal of Oncology Practice, 2019, 15, 575-583.	2.5	7
32	State of Cancer Care in America: Reflections on an Inaugural Year. Journal of Oncology Practice, 2019, 15, 163-165.	2.5	2
33	Assessing an ASCO Decision Aid for Improving the Accuracy and Attribution of Serious Adverse Event Reporting From Investigators to Sponsors. Journal of Oncology Practice, 2019, 15, e1050-e1065.	2.5	3
34	Palbociclib in Patients With Pancreatic and Biliary Cancer With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology, 2019, 3, 1-8.	3.0	46
35	Pembrolizumab (P) in patients (pts) with metastatic breast cancer (MBC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.. Journal of Clinical Oncology, 2019, 37, 1014-1014.	1.6	29
36	Palbociclib (P) in patients (pts) with non-small cell lung cancer (NSCLC) with <i>CDKN2A</i> alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.. Journal of Clinical Oncology, 2019, 37, 9041-9041.	1.6	7

#	ARTICLE	IF	CITATIONS
37	Impact of broadening clinical trial eligibility criteria for advanced non-small cell lung cancer patients: Real-world analysis.. Journal of Clinical Oncology, 2019, 37, LBA108-LBA108.	1.6	10
38	Hypertension and use of bevacizumab among patients treated in community settings.. Journal of Clinical Oncology, 2019, 37, e18279-e18279.	1.6	0
39	Use, attitudes, and perceptions of tumor genomic testing: Survey of TAPUR physicians.. Journal of Clinical Oncology, 2019, 37, 6531-6531.	1.6	1
40	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. Archives of Pathology and Laboratory Medicine, 2018, 142, 1242-1253.	2.5	120
41	A New Look at the State of Cancer Care in America. Journal of Oncology Practice, 2018, 14, 397-399.	2.5	3
42	Rationale and Design of the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology, 2018, 2018, 1-14.	3.0	98
43	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. Journal of Clinical Oncology, 2018, 36, 1631-1641.	1.6	668
44	Impact on Oncology Practices of Including Drug Costs in Bundled Payments. Journal of Oncology Practice, 2018, 14, e259-e268.	2.5	7
45	The State of Oncology Practice in America, 2018: Results of the ASCO Practice Census Survey. Journal of Oncology Practice, 2018, 14, e412-e420.	2.5	114
46	Understanding the Role of Advanced Practice Providers in Oncology in the United States. Journal of Oncology Practice, 2018, 14, e518-e532.	2.5	48
47	Understanding the role of advanced practice providers in oncology in the United States. JAAPA: Official Journal of the American Academy of Physician Assistants, 2018, 31, 1-12.	0.3	7
48	Palbociclib (P) in patients (Pts) with pancreatic cancer (PC) and gallbladder or bile duct cancer (GBC) with <i>CDKN2A</i> alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. Journal of Clinical Oncology, 2018, 36, 2532-2532.	1.6	27
49	Understanding the Role of Advanced Practice Providers in Oncology in the United States. Journal of the Advanced Practitioner in Oncology, 2018, 9, 585-598.	0.4	7
50	Insurance denials for cancer clinical trial participation after the Affordable Care Act mandate. Cancer, 2017, 123, 2893-2900.	4.1	13
51	Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncologyâ€“Friends of Cancer Research Organ Dysfunction, Prior or Concurrent Malignancy, and Comorbidities Working Group. Journal of Clinical Oncology, 2017, 35, 3753-3759.	1.6	130
52	Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement. Journal of Clinical Oncology, 2017, 35, 3737-3744.	1.6	331
53	Reaffirming and Clarifying the American Society of Clinical Oncologyâ€™s Policy Statement on the Critical Role of Phase I Trials in Cancer Research and Treatment. Journal of Clinical Oncology, 2017, 35, 139-140.	1.6	22
54	National Cancer Instituteâ€“American Society of Clinical Oncology Teams in Cancer Care Project. Journal of Oncology Practice, 2016, 12, 955-958.	2.5	27

#	ARTICLE	IF	CITATIONS
55	Association Between Geographic Access to Cancer Care and Receipt of Radiation Therapy for Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 719-728.	0.8	78
56	Reply to N. Lowy et al and to J. Dhanda et al. <i>Journal of Clinical Oncology</i> , 2016, 34, 1708-1709.	1.6	0
57	Addressing Administrative and Regulatory Burden in Cancer Clinical Trials: Summary of a Stakeholder Survey and Workshop Hosted by the American Society of Clinical Oncology and the Association of American Cancer Institutes. <i>Journal of Clinical Oncology</i> , 2016, 34, 3796-3802.	1.6	29
58	Predictors of insurance denials for cancer clinical trial participation after ACA mandate.. <i>Journal of Clinical Oncology</i> , 2016, 34, e14047-e14047.	1.6	0
59	Reviewing Cancer Care Team Effectiveness. <i>Journal of Oncology Practice</i> , 2015, 11, 239-246.	2.5	129
60	Intentional Approach to Team-Based Oncology Care: Evidence-Based Teamwork to Improve Collaboration and Patient Engagement. <i>Journal of Oncology Practice</i> , 2015, 11, 247-248.	2.5	11
61	Reply to H.G. Muntz et al. <i>Journal of Oncology Practice</i> , 2015, 11, 428-428.	2.5	0
62	Teams and Teamwork During a Cancer Diagnosis: Interdependency Within and Between Teams. <i>Journal of Oncology Practice</i> , 2015, 11, 231-238.	2.5	72
63	Improving the Evidence Base for Treating Older Adults With Cancer: American Society of Clinical Oncology Statement. <i>Journal of Clinical Oncology</i> , 2015, 33, 3826-3833.	1.6	343
64	Association Between Geographic Access to Cancer Care, Insurance, and Receipt of Chemotherapy: Geographic Distribution of Oncologists and Travel Distance. <i>Journal of Clinical Oncology</i> , 2015, 33, 3177-3185.	1.6	187
65	Recommendations for Obesity Clinical Trials in Cancer Survivors: American Society of Clinical Oncology Statement. <i>Journal of Clinical Oncology</i> , 2015, 33, 3961-3967.	1.6	50
66	Modernizing Eligibility Criteria for Molecularly Driven Trials. <i>Journal of Clinical Oncology</i> , 2015, 33, 2815-2820.	1.6	80
67	Association between geographic access to cancer care and receipt of chemotherapy: Geographic distribution of oncologists and travel distance.. <i>Journal of Clinical Oncology</i> , 2015, 33, e17561-e17561.	1.6	0
68	The Changing Face of Research in Community Practice. <i>Journal of Oncology Practice</i> , 2014, 10, 155-160.	2.5	4
69	Access to Chemotherapy Services by Availability of Local and Visiting Oncologists. <i>Journal of Oncology Practice</i> , 2014, 10, 26-31.	2.5	47
70	Enhancing the American Society of Clinical Oncology Workforce Information System With Geographic Distribution of Oncologists and Comparison of Data Sources for the Number of Practicing Oncologists. <i>Journal of Oncology Practice</i> , 2014, 10, 32-38.	2.5	70
71	Where Do Patients With Cancer in Iowa Receive Radiation Therapy?. <i>Journal of Oncology Practice</i> , 2014, 10, 20-25.	2.5	26
72	Projected Supply of and Demand for Oncologists and Radiation Oncologists Through 2025: An Aging, Better-Insured Population Will Result in Shortage. <i>Journal of Oncology Practice</i> , 2014, 10, 39-45.	2.5	194

#	ARTICLE	IF	CITATIONS
73	Assessment of Risk Evaluation and Mitigation Strategies in Oncology: Summary of the Oncology Risk Evaluation and Mitigation Strategies Workshop. <i>Journal of Oncology Practice</i> , 2013, 9, e24-e39.	2.5	10
74	The National Cancer Institute's American Society of Clinical Oncology Cancer Trial Accrual Symposium: Summary and Recommendations. <i>Journal of Oncology Practice</i> , 2013, 9, 267-276.	2.5	121
75	Tracking the Workforce: The American Society of Clinical Oncology Workforce Information System. <i>Journal of Oncology Practice</i> , 2013, 9, 3-8.	2.5	48
76	The Impact of Insurance on Access to Cancer Clinical Trials at a Comprehensive Cancer Center. <i>Clinical Cancer Research</i> , 2010, 16, 5997-6003.	7.0	38
77	Challenges to National Cancer Institute-Supported Cooperative Group Clinical Trial Participation: An ASCO Survey of Cooperative Group Sites. <i>Journal of Oncology Practice</i> , 2010, 6, 114-117.	2.5	19
78	The Impact of the Privacy Rule on Cancer Research: Variations in Attitudes and Application of Regulatory Standards. <i>Journal of Clinical Oncology</i> , 2009, 27, 4014-4020.	1.6	9
79	Ethics in Oncology: Consulting for the Investment Industry. <i>Journal of Clinical Oncology</i> , 2007, 25, 444-446.	1.6	10